01—Abstract
Summary
Summary of the 8-K filed April 4, 2024. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation (BSX) has filed an 8-K to disclose that both the Company and Axonics, Inc. received a "Second Request" from the U.S. Federal Trade Commission (FTC) on April 3, 2024.
This request is in connection with the FTC's ongoing review of the proposed merger between Boston Scientific and Axonics, originally announced on January 8, 2024. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act). The waiting period will now remain in effect until 30 days after both parties have substantially complied with the FTC's information requests, unless terminated earlier or further extended.
Boston Scientific and Axonics expect to respond promptly and cooperate fully with the FTC. Consequently, the closing of the merger is now anticipated in the second half of 2024, a shift from previous expectations.
This delay is subject to the HSR Act waiting period and other customary closing conditions. Investors should monitor the progress of the FTC's review and the Company's subsequent disclosures regarding the merger's completion timeline and any potential impact on strategic integration.
02—Key points
Key Highlights
- Boston Scientific and Axonics received a "Second Request" from the FTC on April 3, 2024, related to the proposed merger.
- The Second Request extends the HSR Act waiting period, delaying the merger's closing.
- The merger is now expected to be completed in the second half of 2024.
- The Company and Axonics plan to respond promptly and cooperate with the FTC.
- The merger remains subject to HSR Act clearance and other customary closing conditions.
- The filing includes a cautionary statement regarding forward-looking statements, highlighting potential risks and uncertainties that could affect future results, including the merger's completion and integration.
03—Questions
Frequently Asked Questions
What is the significance of the "Second Request" from the FTC?
A "Second Request" is an official notice from the FTC indicating that they require more information to complete their antitrust review of the proposed merger. This is a standard part of the HSR Act review process and signifies that the FTC is conducting a more in-depth investigation into potential competitive concerns.
How does the Second Request impact the timeline for the Axonics merger?
The issuance of a Second Request automatically extends the waiting period under the HSR Act. The waiting period will not expire until 30 days after both Boston Scientific and Axonics have substantially complied with the FTC's information requests. This effectively pushes the expected closing date to the second half of 2024.
What are the next steps for Boston Scientific and Axonics regarding the FTC review?
Boston Scientific and Axonics intend to respond promptly to the Second Request and continue to cooperate fully with the FTC throughout its review process. The parties will work towards satisfying the FTC's information needs to facilitate the clearance of the merger.
Are there any other conditions to closing the merger besides FTC approval?
Yes, while the FTC review is a significant hurdle, the merger is also subject to other customary closing conditions. These would typically include regulatory approvals in other jurisdictions (if applicable), shareholder approvals (if required), and the absence of any material adverse changes.
04—Continue